Cargando…

Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines

The objective of this study was to compare recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018) with other recently published guidelines for treating bipolar disorder. We reviewed a total of five recently published global treatment guidelines and compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Jong-Hyun, Bahk, Won-Myong, Woo, Young Sup, Lee, Jung Goo, Kim, Moon-Doo, Sohn, InKi, Shim, Se-Hoon, Jon, Duk-In, Seo, Jeong Seok, Kim, Won, Song, Hoo-Rim, Min, Kyung Joon, Yoon, Bo-Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478090/
https://www.ncbi.nlm.nih.gov/pubmed/30905116
http://dx.doi.org/10.9758/cpn.2019.17.2.155
_version_ 1783413126718291968
author Jeong, Jong-Hyun
Bahk, Won-Myong
Woo, Young Sup
Lee, Jung Goo
Kim, Moon-Doo
Sohn, InKi
Shim, Se-Hoon
Jon, Duk-In
Seo, Jeong Seok
Kim, Won
Song, Hoo-Rim
Min, Kyung Joon
Yoon, Bo-Hyun
author_facet Jeong, Jong-Hyun
Bahk, Won-Myong
Woo, Young Sup
Lee, Jung Goo
Kim, Moon-Doo
Sohn, InKi
Shim, Se-Hoon
Jon, Duk-In
Seo, Jeong Seok
Kim, Won
Song, Hoo-Rim
Min, Kyung Joon
Yoon, Bo-Hyun
author_sort Jeong, Jong-Hyun
collection PubMed
description The objective of this study was to compare recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018) with other recently published guidelines for treating bipolar disorder. We reviewed a total of five recently published global treatment guidelines and compared treatment recommendation of the KMAP-BP 2018 with those of other guidelines. For initial treatment of mania, there were no significant differences across treatment guidelines. All guidelines recommended mood stabilizer (MS) or atypical antipsychotic (AAP) monotherapy or a combination of an MS with an AAP as a first-line treatment strategy for mania. However, the KMAP-BP 2018 did not prefer monotherapy with MS or AAP for psychotic mania. Quetiapine, olanzapine and aripiprazole were the first-line AAPs for nearly all phases of bipolar disorder across guidelines. Most guidelines advocated newer AAPs as first-line treatment options for all phases while lamotrigine was recommended for depressive and maintenance phases. Lithium and valproic acid were commonly used as MSs in all phases of bipolar disorder. As research evidence accumulated over time, recommendations of newer AAPs (such as asenapine, cariprazine, paliperidone, lurasidine, long-acting injectable risperidone and aripiprazole once monthly) became prominent. KMAP-BP 2018 guidelines were similar to other guidelines, reflecting current changes in prescription patterns for bipolar disorder based on accumulated research data. Strong preference for combination therapy was characteristic of KMAP-BP 2018, predominantly in the treatment of psychotic mania and severe depression. Further studies were needed to address several issues identified in our review.
format Online
Article
Text
id pubmed-6478090
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean College of Neuropsychopharmacology
record_format MEDLINE/PubMed
spelling pubmed-64780902019-05-07 Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines Jeong, Jong-Hyun Bahk, Won-Myong Woo, Young Sup Lee, Jung Goo Kim, Moon-Doo Sohn, InKi Shim, Se-Hoon Jon, Duk-In Seo, Jeong Seok Kim, Won Song, Hoo-Rim Min, Kyung Joon Yoon, Bo-Hyun Clin Psychopharmacol Neurosci Review The objective of this study was to compare recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018) with other recently published guidelines for treating bipolar disorder. We reviewed a total of five recently published global treatment guidelines and compared treatment recommendation of the KMAP-BP 2018 with those of other guidelines. For initial treatment of mania, there were no significant differences across treatment guidelines. All guidelines recommended mood stabilizer (MS) or atypical antipsychotic (AAP) monotherapy or a combination of an MS with an AAP as a first-line treatment strategy for mania. However, the KMAP-BP 2018 did not prefer monotherapy with MS or AAP for psychotic mania. Quetiapine, olanzapine and aripiprazole were the first-line AAPs for nearly all phases of bipolar disorder across guidelines. Most guidelines advocated newer AAPs as first-line treatment options for all phases while lamotrigine was recommended for depressive and maintenance phases. Lithium and valproic acid were commonly used as MSs in all phases of bipolar disorder. As research evidence accumulated over time, recommendations of newer AAPs (such as asenapine, cariprazine, paliperidone, lurasidine, long-acting injectable risperidone and aripiprazole once monthly) became prominent. KMAP-BP 2018 guidelines were similar to other guidelines, reflecting current changes in prescription patterns for bipolar disorder based on accumulated research data. Strong preference for combination therapy was characteristic of KMAP-BP 2018, predominantly in the treatment of psychotic mania and severe depression. Further studies were needed to address several issues identified in our review. Korean College of Neuropsychopharmacology 2019-03 2019-04-30 /pmc/articles/PMC6478090/ /pubmed/30905116 http://dx.doi.org/10.9758/cpn.2019.17.2.155 Text en Copyright © 2019, Korean College of Neuropsychopharmacology This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Jeong, Jong-Hyun
Bahk, Won-Myong
Woo, Young Sup
Lee, Jung Goo
Kim, Moon-Doo
Sohn, InKi
Shim, Se-Hoon
Jon, Duk-In
Seo, Jeong Seok
Kim, Won
Song, Hoo-Rim
Min, Kyung Joon
Yoon, Bo-Hyun
Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines
title Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines
title_full Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines
title_fullStr Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines
title_full_unstemmed Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines
title_short Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines
title_sort korean medication algorithm for bipolar disorder 2018: comparisons with other treatment guidelines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478090/
https://www.ncbi.nlm.nih.gov/pubmed/30905116
http://dx.doi.org/10.9758/cpn.2019.17.2.155
work_keys_str_mv AT jeongjonghyun koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT bahkwonmyong koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT wooyoungsup koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT leejunggoo koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT kimmoondoo koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT sohninki koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT shimsehoon koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT jondukin koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT seojeongseok koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT kimwon koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT songhoorim koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT minkyungjoon koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines
AT yoonbohyun koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines